Investigation of safety and clinical usefulness of natural indigo for patients with active ulcerative colitis

Investigation of safety and clinical usefulness of natural indigo for patients with active ulcerative colitis - Investigation of safety and clinical usefulness of natural indigo for patients with active ulcerative colitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016526

Enrollment

Registered

2015-02-13

Start date

2015-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

Quig-Dai 2g daily (1g/once twice a day) Duration of treatment is 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Patients have been diagnosed as ulcerative colitis (Japanese Criteria) 2 Patients with mild to moderate active disease 3 Age more than 20 years old 4 Informed consent has been obtained

Exclusion criteria

Exclusion criteria: 1 Patients with colitis-associated dysplasia or cancer 2 Patients who are suspected with infectious colitis 3 Patients with severe colonic stenosis 4 Patients who needs colectomy after enroll of this study 5 Previous adverse effects to Chinese medicine

Design outcomes

Primary

Measure	Time frame
The incidence of adverse effect The rate of clinical improvement	—

Secondary

Measure	Time frame
he rate of clinical remission The rate of endoscopic remission	—

Countries

Japan

Contacts

Public ContactMakoto Naganuma

Keio University Hospital Center for Diagnostic and Therapeutic Endoscopy

nagamakoto@z7.keio.jp03-3353-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026